A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. - Wikidata - awgldk - TriplyDB

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

http://www.wikidata.org/entity/Q53298171

about

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.Two drugs are better than one. A short history of combined therapy of ovarian cancer Ovarian cancer standard of care: are there real alternatives?Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer Advanced ovarian cancer: what should be the standard of care?Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment Update on immune checkpoint inhibitors in gynecological cancers Role of cytoreductive surgery in recurrent ovarian cancer.A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.Retrospective comparison of chemotherapy-induced myelotoxicity in patients with ovarian cancer under and over 60 years of age.A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma.A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer.

P2860

Q21563402-D15AE4BD-D4C8-477B-82D9-5C8486245283 Q24186509-431B5D58-B35D-4C39-98B2-221F3B8E7E58 Q24235235-8F6D3385-C607-422A-B943-5E19AE06EDBC Q24236119-73B05ECF-3652-40DF-BF02-24A26196213D Q24242032-90A82547-911A-45CB-951C-EA8A9A13FF3F Q24244876-A27F4D8D-4E3A-427C-B54B-C29FCF1989BB Q24650289-ED9D3768-E991-4E2C-A4D8-41E061B4DD9F Q25257587-F2BDF090-4EF0-4A60-BC0A-DDB8870EFBCA Q26770477-0CE16876-D8E3-4069-816A-9D0A0E888668 Q26862249-665B569B-B824-4E2D-808F-C1977B662ECA Q27011840-DD0F87E0-08B2-46C8-AEA4-6586FF840A37 Q27852053-350B43DC-7B23-418E-AE84-D4DE69CB26C9 Q28073057-FED048CC-65BA-4FF1-9013-BF30C913C95E Q28076497-40227270-E4FB-4333-8E02-D8EBBA284D8A Q30378801-841E5B36-0B10-4AD8-86E4-20FAA2D3D5CC Q30430866-CE9AE869-F9EF-4D37-814B-63A7D052B30B Q30436714-2FC86E3C-7716-47CA-AB8B-F99A1B9AC5EE Q30494709-609AEE52-F024-4F57-BB06-859AD7B867C5 Q30689000-0A9464C6-E236-4980-8991-954934575474 Q33372127-FBAFFF95-8572-450B-9ED9-37B46B413022 Q33374097-CD1A483C-D98B-447E-9C1F-61F6618454C8 Q33374599-B6CD7A88-708E-426B-8532-69BCEE13B432 Q33376928-9C4C6BC5-65C2-486C-9FC2-69E916662E4A Q33377058-DE068E81-CF8B-456D-A7C2-178C4741A98A Q33379831-F834BF63-928F-4FC9-B28D-F7FDDAA48AA5 Q33387755-9AFFB025-6FC3-4B7B-99DA-72D817DA1ADC Q33392795-9EE21096-DC36-41E9-AA2D-D9A306D3A899 Q33395064-60B4E182-ADDD-42AB-B456-224E657B48D0 Q33396235-7DD80C7C-BC94-451C-A025-DA1D6451070B Q33401454-796BBC50-5C09-494A-9AD7-692969AD8494 Q33409319-342AE44B-D966-4C54-A6AB-E0B1BB8D36DB Q33422082-276A1927-56FD-4BBD-AD8E-B3294113AB2C Q33436678-A7E2E45A-B452-40E2-9271-D0B18476ED86 Q33488520-597AC67F-5F13-44C4-9190-958ACDFA3FF6 Q33553922-372E604F-70EC-4A00-845A-4DA82F926CE8 Q33589984-4B016D81-A68B-4E3B-B789-6B3F8E9B7C29 Q33596742-6042357A-2D24-47EE-8EB2-601A9455ADC3 Q33626973-41C9C87A-7B72-4E7B-92A2-546DCAEB4608 Q33710438-D3444638-0DEB-480C-A1B3-92F3930324DD Q33774695-097B3710-0679-424E-929E-23A7022B6BAF

P2860

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

http://www.wikidata.org/entity/Q53298171

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

A randomized clinical trial of ...... e treatment of ovarian cancer.

@en

A randomized clinical trial of ...... e treatment of ovarian cancer.

@nl

type

label

A randomized clinical trial of ...... e treatment of ovarian cancer.

@en

A randomized clinical trial of ...... e treatment of ovarian cancer.

@nl

prefLabel

A randomized clinical trial of ...... e treatment of ovarian cancer.

@en

A randomized clinical trial of ...... e treatment of ovarian cancer.

@nl

P1433

Q53298171-5A8EA4CB-6FD7-4C1F-9BAC-B6A64D39D11E

P1476

Q53298171-6202C2CB-EACD-49E3-947E-A8E3297F189B

P2093

Q53298171-0BF13093-48E6-40ED-80C1-B538CB295439

Q53298171-17182DC5-FCE1-481A-BBAE-24148486F800

Q53298171-20BD0A6F-6A6C-4F10-8545-2751327096B9

Q53298171-3EBFE126-213B-4D60-905A-54FD7661B021

Q53298171-414B10A7-7A7C-41ED-8586-3B933F3430E0

Q53298171-4D57F89C-22C0-4D39-9097-477F03F73869

Q53298171-4F46BDD1-CFE6-4208-B71B-F83EE404B49D

Q53298171-68041A00-B517-41F1-8889-E138DAC80F10

Q53298171-713422DB-7C21-4514-BD91-34F62473CA62

Q53298171-75A15893-54CA-4CA4-AB23-547D80997564

P304

Q53298171-37B3FB62-014F-4307-8192-1979B6E26692

P31

Q53298171-103AB6D6-AEF3-41FA-8CBF-48CD9DECE24D

P356

Q53298171-12CF73D5-6975-40CE-AFCE-4A97919779EE

P407

Q53298171-B7AC916B-5695-4AB9-8660-761418DA3D30

P433

Q53298171-F6FBA782-54B8-4151-AD25-46547BEB376F

P478

Q53298171-57147D3D-0016-4902-8375-39427BF989BA

P577

Q53298171-5BB83FFD-A31C-4C15-B5B7-DF1BE45CC91E

P698

Q53298171-19D998F8-27C5-43B9-8C44-2AD7E2CBCA78

P921

Q53298171-5E705A54-BF3D-43E7-BCF3-64E38B463FDF

P356

P1433

Journal of the National Cancer Institute

P1476

A randomized clinical trial of ...... e treatment of ovarian cancer.

@en

P2093

Andreas du Bois

http://www.w3.org/2001/XMLSchema#string

Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group

http://www.w3.org/2001/XMLSchema#string

Barbara Richter

http://www.w3.org/2001/XMLSchema#string

Christian Jackisch

http://www.w3.org/2001/XMLSchema#string

Günther Emons

http://www.w3.org/2001/XMLSchema#string

Hans-Joachim Lück

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Adams

http://www.w3.org/2001/XMLSchema#string

Jacobus Pfisterer

http://www.w3.org/2001/XMLSchema#string

Matthias Warm

http://www.w3.org/2001/XMLSchema#string

Serban Costa

http://www.w3.org/2001/XMLSchema#string

P304

1320-1329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJG036

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12953086

http://www.w3.org/2001/XMLSchema#string

P921